Serum adiponectin levels have been seen to significantly decrease in breast-cancer patients, while antiproliferative effects of adiponectin, as well as cell cycle inhibition and activation of apoptosis have been verified in most studies [36]. Here, ADIPOQ is linked to breast carcinoma.